drughunter.com

Top Small Molecule M&A Transactions in 2021

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other articles you may be interested in

Another KRASG12C Inhibitor in Ph. III, Bayer’s Massive FXIa Ph. III Clinical Trial, and 21 Other Molecules in the News

In this update of small molecules in the news for February 2023, we will cover recent: - Molecules in Motion : clinical trial updates and FDA filings - Negative Readouts : halted, discontinued or altered clinical trials - Million-Dollar Molecules : recent M&A’s, IPOs, and other fundraising - Potential Approvals : recent NDA filings and [...]

KIN-3248: Overcoming FGFR Resistance with a Next-Generation Pan-FGFR Inhibitor

KIN-3248 (Kinnate Biopharma) is a next-generation, irreversible, pan-fibroblast growth factor receptor inhibitor (FGFRi) in a first-in-human (FIH) dose-escalation study (NCT05242822) in adults with advanced tumors harboring FGFR2 and FGFR3 gene alterations. The program is an excellent case study for rational covalent drug design to address kinase mutations while maintaining sufficient PK properties for oral daily dosing in humans.

A PARP1i, GLP-1Ra, and Other Million-Dollar Molecules from Nov. ‘23

Several multi-million dollar acquisitions or license agreements took place in November 2023 for hot drug targets, with assets from selective PARP1 inhibitors to GLP1R agonists, and others. This recent news roundup highlights the notable acquisitions by pharma companies for rights to molecules in a range of different indications, with illustrative patent examples for undisclosed structures.

Billion-Dollar Molecules: M4 Modulators, GLP-1 Biased Agonists, and an SSTR2 Radiotherapy

Last December, the pharmaceutical industry witnessed many important updates for clinical molecules, ranging from neurology-based therapies to anti-tumors and radiopharmaceuticals, in addition to the unfortunate discontinuations. In case you missed it, here is a recap of the most notable news updates in the pharma world for December 2023

Patent Highlights: Allosteric AR Modulators, Glycogen Synthase Inhibitors, and More

This article highlights million-dollar molecules that were recently in the news with related patent applications that give clues to their structures and properties. This edition includes Maze’s glycogen synthase 1 (GYS1) inhibitors that were recently licensed to Sanofi, allosteric androgen receptor (AR) modulators that may be of interest to targeted protein degradation researchers, brain-penetrant HER2 and ROCK2 inhibitors, and MDM2 degraders.